Yep. Agree completely.
At the moment, I am doing better in another stock with the proceeds, but I have to do better after CGT, which is hard - so will it last?.
The strange thing is, ACR is not a lost cause. Some products succeed with minimal marketing, word of mouth is powerful to be sure. Axiron might do that. Lilly might wind up having to pay the bonus anyway. Axiron may keep paying the divvy for a decade. In that time the pipeline might actually spit out something good.
Who knows really? That's why this one is so hard....
Add to My Watchlist
What is My Watchlist?
